

Richard Davis
President and Chief Executive Officer

Francis L. Weng, MD, MSCE
Chief, Transplant Division

February 7, 2024

The SRTR has reported that the actual 3-year patient survival at Cooperman Barnabas is 90.60%, vs. 90.92% for the U.S.

The SRTR has tried to account for the effects of the COVID-19 pandemic and has erroneously reported the 3-year survival at CBMC as “64.13%”.

This false number is due to statistical modelling, is obviously inaccurate and far underestimates the actual 3-year patient survival at CBMC.

We anticipate future reports will be modified for a more accurate reflection of estimated survival.

**Francis Weng, MD
Transplant Program Director
Cooperman (Saint) Barnabas Medical Center
NJSB**